Nature Machine IntelligenceBioinformaticsPeer-reviewed journal article
A deep learning framework for high-throughput mechanism-driven phenotype compound screening
Thai-Hoang PhamiD, Yue QiuiD, Jucheng Zeng, Lei XieiD, Ping ZhangiD
Abstract
Target-based high-throughput compound screening dominates conventional one-drug-one-gene drug discovery process. However, the readout from the chemical modulation of a single protein is poorly correlated with phenotypic response of organism, leading to high failure rate in drug development. Chemical-induced gene expression profile provides an attractive solution to phenotype-based screening. However, the use of such data is currently limited by their sparseness, unreliability, and relatively low throughput. Several methods have been proposed to impute missing values for gene expression datasets. However, few existing methods can perform de novo chemical compound screening. In this study, we propose a mechanism-driven neural network-based method named DeepCE (Deep Chemical Expression) which utilizes graph convolutional neural network to learn chemical representation and multi-head attention mechanism to model chemical substructure-gene and gene-gene feature associations. In addition, we propose a novel data augmentation method which extracts useful information from unreliable experiments in L1000 dataset. The experimental results show that DeepCE achieves the superior performances not only in de novo chemical setting but also in traditional imputation setting compared to state-of-the-art baselines for the prediction of chemical-induced gene expression. We further verify the effectiveness of gene expression profiles generated from DeepCE by comparing them with gene expression profiles in L1000 dataset for downstream classification tasks including drug-target and disease predictions. To demonstrate the value of DeepCE, we apply it to patient-specific drug repurposing of COVID-19 for the first time, and generate novel lead compounds consistent with clinical evidences. Thus, DeepCE provides a potentially powerful framework for robust predictive modeling by utilizing noisy omics data as well as screening novel chemicals for the modulation of systemic response to disease.
- organism: human
- assay: bulk RNA-seq
- research focus: drug response / drug discovery
- approach: deep learning
- Citations
- 219
- FWCI
- 19.24
- Field percentile
- top 1%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Predicting compound activity from phenotypic profiles and chemical structures
Nikita Moshkov, Tim Becker, … Juan C. Caicedo·Nature CommunicationsPeer-reviewed·Apr 8, 2023
- DeepSide: A Deep Learning Framework for Drug Side Effect Prediction
Onur Can Üner, Ramazan Gökberk Cinbiş, … A. Ercüment Çiçek·bioRxiv·Nov 18, 2019
- Evaluation of network architecture and data augmentation methods for deep learning in chemogenomics
Benoît Playe, Véronique Stoven·Journal of CheminformaticsPeer-reviewed·Feb 10, 2020
- Predictive Modeling of Multiplex Chemical Phenomics for Novel Cells and Patients: Applied to Personalized Alzheimer's Disease Drug Repurposing
- Deep Learning for Virtual Screening: Five Reasons to Use ROC Cost Functions
V. Golkov, A. Becker, … D. Cremers·bioRxiv·Jun 25, 2020
- DR3E-Net: Drug Repurposing Network Framework Based on Deep Embedding, Differentially Expressed Genes, and Drug Side Effects
Youngmin Bhak, Joon Ho Park, Hyun Wook Han·bioRxiv·Jun 15, 2024